hackint0sh/New-Dataset huggingface dataset:
Participants have undergone or will undergo the standard diagnostic pathway appropriate for their conditions as part of routine clinical practice. All instrumental examinations and endoscopic ultrasound procedures are integral to the standard diagnostic and therapeutic approach for pancreatic diseases. conditions: Pancreas Neoplasm conditions: Cancer of Pancreas conditions: Pancreatitis conditions: Neuroendocrine Tumors studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 12000 type: ESTIMATED measure: Registry for images and videos sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS San Raffaele Hospital status: RECRUITING city: Milan zip: 20132 country: Italy name: Matteo Tacelli, MD role: CONTACT email: tacelli.matteo@hsr.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06344494 id: INTELICE-CTP-2401 briefTitle: Cardiac Interventional ICE Imaging Trial acronym: INTELICE overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2026-05 date: 2024-04-03 date: 2024-04-04 name: ICE Intelligent Healthcare Co., Ltd class: INDUSTRY briefSummary: The INTELICE trial is a prospective, multicenter, 1:1 randomized controlled non-inferiority study. It aims to compare a novel intracardiac echography (ICE) catheter and combined ultrasound system with existing commercial ones. The evaluation will be conducted on patients undergoing planned intracardiac interventional process. conditions: Structural Heart Diseases conditions: Atrial Septal Defect conditions: Patent Foramen Ovale conditions: Arrhythmias, Cardiac conditions: Atrial Fibrillation conditions: Supraventricular Tachycardia conditions: Valve Disease, Heart studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 130 type: ESTIMATED name: Arch EchoTM Intracardiac Ultrasound catheter and ultrasound system name: SOUNDSTAR 3D Diagnostic Ultrasound catheter and ACUSON P500 system measure: Image quality measure: Image quality measure: Procedure success measure: Technical success measure: Procedure time measure: Device performance sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Anzhen Hospital, Capital Medical University city: Beijing state: Bejing zip: 100011 country: China name: Deyong Long, MD, PhD role: CONTACT phone: 64412431 phoneExt: 0086010 email: dragon2008@vip.sina.com name: Ribo Tang, MD, PhD role: SUB_INVESTIGATOR lat: 39.9075 lon: 116.39723 facility: The First People's Hospital of Changzhou city: Changzhou state: Jiangsu zip: 213004 country: China name: Ling Yang, MD role: CONTACT phone: 68873108 phoneExt: 00860519 email: Yangling369@czfph.com name: Ling Yang, MD role: PRINCIPAL_INVESTIGATOR name: Bo Qian, MD role: SUB_INVESTIGATOR lat: 31.77359 lon: 119.95401 facility: The First Hospital Of Jilin University city: Changchun state: Jilin zip: 130021 country: China name: Shuyan Li, MD, PhD role: CONTACT phone: 88782222 phoneExt: 00860431 email: shuyanli1992@163.com name: Shuyan Li, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Hongbo Meng role: SUB_INVESTIGATOR lat: 43.88 lon: 125.32278 facility: Shanghai General Hospital city: Shanghai state: Shanghai zip: 200081 country: China name: Songwen Chen, MD, PhD role: CONTACT phone: 18017638339 phoneExt: 0086 name: Songwen Chen, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Juan Sun role: SUB_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06344481 id: CL-00003 briefTitle: The Hyalex First-in-Human Study overallStatus: RECRUITING date: 2024-03-07 date: 2026-09 date: 2026-09 date: 2024-04-03 date: 2024-04-12 name: Hyalex Orthopaedics, Inc. class: INDUSTRY briefSummary: The Hyalex First-in-Human Study is a prospective, multicenter, open-label, single-arm, 2-phase, first-in-human study to evaluate the safety and technical performance of the HYALEX Knee Cartilage System for replacement of loss of articular cartilage and bone of the knee femoral condyles in symptomatic patients who require surgical treatment. conditions: Cartilage Injury studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Surgical (Hyalex Cartilage Knee Implant) measure: Freedom from implant rejection and infection. measure: Change in the Knee Injury & Osteoarthritis Outcome Score (KOOS) from baseline at 12 months. sex: ALL minimumAge: 21 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SPORTO status: RECRUITING city: Łódź zip: 09-038 country: Poland name: Klaudia Marchewa role: CONTACT email: marchewa.klaudia@gmail.com name: Marcin Domzalski, M.D. role: PRINCIPAL_INVESTIGATOR lat: 51.75 lon: 19.46667 hasResults: False
nctId: NCT06344468 id: 531393 briefTitle: The Effect of Early Mobilization on Sleep, Physiological Parameters, and Length of Stay in ICU overallStatus: COMPLETED date: 2023-04-12 date: 2023-06-05 date: 2024-03-04 date: 2024-04-03 date: 2024-04-03 name: Istanbul University - Cerrahpasa (IUC) class: OTHER briefSummary: The goal of this is randomized controlled study to examine the effect of early mobilization on sleep, physiological parameters, and length of stay in the intensive care unit (ICU).
Early mobilization will begin in the experimental group after sedation is discontinued within the first 12 hours and its effects disappear. In early mobilization, in the evaluation of in-bed mobilization, physiological parameters (respiratory rate, sPO 2, heart rate, blood pressure, body temperature, pain) will be evaluated and recorded in the supine, semi-fowler position. In out-of-bed mobilization, the patient's physiological parameters (respiratory rate, sPO 2, heart rate, blood pressure, body temperature, pain) will be determined and recorded before mobilization and when the head is in a 45˚ upward position. Surgical wounds and dressing areas, if any, are protected, drains are identified, care is taken not to remove equipment such as urinary catheters or nasogastric tubes, when the patient is seated on the edge of the bed with the help of a nurse, when he/she is stood up next to the bed with the support of the nurse, when he/she is made to sit in a chair next to the bed and when he/she is in a chair. While sitting, 1st minute, 5th minute, 10th minute respiratory rate, sPO2, heart rate, blood pressure, body temperature values and pain levels will be recorded and these data will be evaluated on their own. During mobilization, if the patient develops chest pain, arrhythmia, hypertension (systolic pressure\>160 mmHg), or hypotension (systolic pressure\<90 mmHg), tachypnea, or hypoxia, a break will be taken and the physician will be consulted. The same procedures will be repeated during the mobilization of the patient in the first 24-36 hours and the necessary records will be made by the researcher.
After admission to the Cardiovascular Surgery ICU, the type, purpose and implementation process of the study will be explained to the patients, and a routine/standard postoperative mobilization procedure will be applied to the patients in the control group. Accordingly, patients will be mobilized in the first 24 hours after surgery, and in the evaluation of in-bed mobilization, their physiological parameters (respiratory rate, sPO 2, heart rate, blood pressure, body temperature, pain) will be evaluated and recorded in the supine, semi-fowler position. In out-of-bed mobilization, the patient's physiological parameters (respiratory rate, sPO 2, heart rate, blood pressure, body temperature, pain) will be determined and recorded before mobilization and when the head is in a 45˚ upward position. Again, arterial blood gas monitoring of the patients in the control group will be performed at maximum 4-hour intervals, and respiratory parameters will be frequently evaluated and recorded. conditions: Early Mobilization conditions: Sleep Quality conditions: Critical Care conditions: Nursing Caries studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 82 type: ACTUAL name: Early Mobilization measure: The length of stay of patients in the intensive care unit measure: The Richards-Campbell Sleep Questionnaire (RCSQ) measure: The Glasgow Coma Scale (GCS) measure: Physiological Parameter - for the experimental group measure: Physiological Parameter - for the control group sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: İstanbul University-Cerrahpaşa Cerrahpaşa School of Medicine city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06344455 id: RCT Delay Discounting briefTitle: Influence of Educational Stimuli From the Pé-de-Meia Program on Delay Discounting Propensity overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-01 date: 2025-07-01 date: 2024-04-03 date: 2024-04-03 name: Federal Institute of Education, Science and Technology of the State of Mato Grosso class: OTHER briefSummary: The goal of this randomized clinical trial is to investigate how the Stay-and-Complete School Incentive Savings, part of the Pé-de-Meia Program, affects decision-making among low-income high school students, particularly their tendency towards delay discounting. This concept describes the preference for immediate gratifications over larger future rewards. The main questions it seeks to answer are:
Researchers will compare the outcomes among groups of students exposed to different types of stimuli (aligned with the program's objectives, contrasting, and a control group without modifications) to see if the specific financial and educational incentives of the Pé-de-Meia Program influence how students value immediate rewards compared to future benefits. This study is expected to contribute to the improvement of public educational policies, encouraging school retention and promoting the educational success of low-income adolescents. conditions: Delay Discounting studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: School Retention and Completion Incentive Savings via Modified Iowa Gambling Task A name: Iowa Gambling Task name: School Retention and Completion Incentive Savings via Modified Iowa Gambling Task B measure: Delay Discounting 1 measure: Delay Discounting 2 measure: decision-making performance under risk and uncertainty measure: loss aversion measure: Loss Frequency-Based Decision Strategy measure: Learning sex: ALL minimumAge: 14 Years maximumAge: 24 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06344442 id: APHP220827 briefTitle: Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial) overallStatus: NOT_YET_RECRUITING date: 2024-05-05 date: 2026-06-05 date: 2026-06-05 date: 2024-04-03 date: 2024-04-03 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Liver transplantation (LT) is a high-risk surgery for hemodynamic instability and haemorrhagic shock with a high-risk of acute kidney injury (AKI). Indeed, the incidence of post-transplant AKI exceeds 50% in some series with 15% of patients requiring renal replacement therapy. Acute kidney injury after LT is a predisposing factor for chronic renal failure which is independently associated with higher morbidity and mortality.
The hypothesis of the present work is that low-dose arginine-vasopressin supplementation reduce posttransplant AKI in liver transplantation. conditions: Acute Kidney Injury Post Liver Transplantation studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective, national multicentre, double-blinded, randomized ,controlled superiority trial with two parallel arms primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: All the clinical teams involved intraoperatively (anaesthetists, nurse anaesthetists and surgeons) and postoperatively (doctors and nurses who will take care of the patient postoperatively) and the families will ignore the allocation of treatments for the duration of the trial,except the nurse in charge of preparing the infusions ,She will ensure respect for the blind whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 304 type: ESTIMATED name: Arginine vasopressin name: Norepinephrine measure: The primary objective is to compare the effect of intraoperative low-dose supplementation of AVP vs norepinephrine infusions on post-transplant Acute Kidney Injury after liver transplantation. measure: To compare into the two arms the number of packed red blood cellsand fresh frozen plasma transfused measure: To compare into the two arms the number of the Number of AKI KDIGO 1 measure: To compare into the two arms the Number of AKI KDIGO 2 measure: To compare into the Number of AKI KDIGO 3 measure: The need for renal replacement for replacement therapy (RRT) in ICU measure: The number of patients remaining on dialysis at the end of the study measure: Average intraoperative norepinephrine concentrations measure: Average intraoperative concentrations of other vasopressors and inotropes (Adrenalin, Dobutamine) measure: Number of platelets transfused intraoperatively measure: Amount of vascular filling solutions intraoperatively measure: Sequential Organ Failure Assessment (SOFA score) measure: Number of days alive outside intensive care unit measure: Mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: URC Lariboisière-Fernand Widal-saint Louis city: Paris zip: 75010 country: France name: Nabila PIZZI role: CONTACT phone: 01 40 05 49 83 phoneExt: +33 email: nabila.pizzi@aphp.fr name: Jaques DURANTEAU, Pr role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06344429 id: STL_CT_0001 briefTitle: Stellest Lenses and Low-concentration Atropine Myopia Control Among Children overallStatus: RECRUITING date: 2023-08-20 date: 2024-08-20 date: 2025-08-20 date: 2024-04-03 date: 2024-04-04 name: Essilor-Polylite Taiwan Co., Ltd. class: INDUSTRY briefSummary: The prevalence of myopia is increasing globally, especially in Asian countries. 70-80% of the young population suffers from myopia, and almost 20% have high myopia. High myopia can easily lead to blinding diseases, including retinal detachment, macular degeneration, and glaucoma. In Taiwan, according to a survey by the National Health Administration, the proportion of myopia among Grade 1 students has exceeded 81%.
Stellest, a myopia control lens based on the myopia defocus theory, is equipped with highly aspheric lenslet technology. In a recent study, compared with single vision lenses, Stellest significantly slowed down the myopia progression reaching 67% and retard axial elongation reaching 64% The purpose of this study is to explore the effectiveness of Stellest Lenses in controlling myopia in Taiwanese children and whether Stellest Lenses combined with low-concentration atropine eye drops can increase the effect of myopia control. conditions: Myopia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: Stellest Lenses name: Stellest Lenses+0.05% atropine name: Single vision Lenses+0.05% atropine measure: Spherical equivalent refraction power measure: Axial length sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Kaohsiung Chang Gung Memorial Hospital status: RECRUITING city: Kaohsiung zip: 833401 country: Taiwan name: Pei-Chang Wu role: CONTACT name: Pei-Chang Wu role: PRINCIPAL_INVESTIGATOR lat: 22.61626 lon: 120.31333 hasResults: False
nctId: NCT06344416 id: RXG-001-2024-CLP (Rex-002) briefTitle: Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2025-03-30 date: 2026-01-30 date: 2024-04-03 date: 2024-04-03 name: Dosentrx Ltd. class: INDUSTRY briefSummary: Primary Objective:
• To evaluate the impact of the ReX technology platform on ribo treatment duration and ribo dose taking adherence as compared to control group. conditions: Any Solid Oral Medication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Study groups primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: A minimum of 50 and a maximum of 200 patient charts are expected to be reviewed for the control study group. whoMasked: PARTICIPANT count: 200 type: ESTIMATED name: Use of ReX to dispense and monitor solid oral medication therapy. measure: Outcome MeasureReX Platform Study Group sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: OHC city: Cincinnati state: Ohio zip: 45242 country: United States lat: 39.12713 lon: -84.51435 hasResults: False
nctId: NCT06344403 id: KY2024-045-02 briefTitle: Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain overallStatus: RECRUITING date: 2024-04-01 date: 2024-10-01 date: 2025-03-01 date: 2024-04-03 date: 2024-04-03 name: Beijing Tiantan Hospital class: OTHER briefSummary: Herpes zoster (HZ) is a skin infection disease which cause severe zoster-associated pain (ZAP) along sensory nerve in the corresponding segment. Evidence for the efficacy of existing local therapies for acute/subacute ZAP is limited. The hypothesis is that patients with acute/subacute ZAP treated with TPIs with local anesthetic and steroids under the basis of standard treatment will show better clinical outcomes compared with subjects treated with standard antiviral medicine treatment only. conditions: Herpes Zoster conditions: Local Infiltration conditions: Acute Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 136 type: ESTIMATED name: analgesic name: Tender point infiltration measure: The presence of postherpetic neuralgia using VAS score measure: visual analogue scale score at each time point measure: Proportion of patients receiving repeated TPIs and block points measure: Consumption of oral drugs at each time point measure: The presence of PHN 3 and month 6 post treatment measure: Patient satisfaction scores on the 5-point Likert scale measure: Quality of life on the Scores on the WHOQOL-BREF measure: Adverse reactions through study completion sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Tiantan Hospital status: RECRUITING city: Beijing state: Beijing zip: 100070 country: China name: Luo Fang, M.D role: CONTACT phone: +86 13611326978 email: 13611326978@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06344390 id: 20210327 briefTitle: Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke overallStatus: RECRUITING date: 2024-04-10 date: 2024-10-31 date: 2024-12-31 date: 2024-04-03 date: 2024-04-03 name: The First Hospital of Hebei Medical University class: OTHER briefSummary: Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function. The patients with cognitive impairment and non-dementia PSCIND after ischemic stroke were randomly divided into two groups. In addition to the basic drugs of ischemic stroke, the patients were given pentothemine sustained release tablets and blank control respectively to observe the effects of pentothemine on cognitive function and neuronal electrical signals in the patients with ischemic PSCIND. It is expected to explore the possible internal biological mechanism by using transcranial Doppler, oxygen-dependent functional magnetic resonance imaging and craniocerebral magnetic resonance pop analysis. Finally, statistical correlation analysis was used to elucidate the specific mechanism of pentoxifylline in improving cognitive function of non-dementia patients with cognitive impairment after ischemic stroke. conditions: Cognitive Impairment studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: Pentoxifylline measure: Pentoxifylline can improve cognitive impairment after ischemic stroke sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: BHan status: RECRUITING city: Shijiazhuang country: China name: Jiaying Rong role: CONTACT phone: 15241876265 email: rjy19982023@163.com lat: 38.04139 lon: 114.47861 hasResults: False
nctId: NCT06344377 id: BETadiposeWOMEN briefTitle: Betaine Supplementation and Lipid Metabolism in Overweight and Obese Pre-menopausal Women overallStatus: NOT_YET_RECRUITING date: 2024-04-21 date: 2025-12-30 date: 2026-12-30 date: 2024-04-03 date: 2024-04-05 name: Poznan University of Life Sciences class: OTHER briefSummary: Obesity represents a serious global health issue with significant consequences, including an increased risk of chronic diseases. Statistics indicate a growing trend of obesity, highlighting the need to seek methods that improve fat tissue metabolism and reduce obesity-related complications. Previous research on animals has shown that betaine, a substance engaged in one-carbon metabolism, may enhance fat oxidation and lower adipose tissue. Therefore, the aim of the research will be to assess the impact of 8-week betaine supplementation on body composition and lipid metabolism markers, as well as expression of genes related to lipid metabolism, in a group of adult women with abdominal obesity.
This study is designed in a placebo-controlled, double-blinded, randomized fashion. The participants will be overweight or obese pre-menopausal females. Upon enrollment, participants will be randomly assigned to one of two parallel groups: betaine (3g/d) or placebo. The supplementation period will last for 8 weeks. There will be three study meetings: T1 before supplementation, T2 after 4 weeks of supplementation, and T3 after 8 weeks of supplementation. Blood will be drawn and body composition measured, and adipose tissue biopsy taken at meetings T1 and T3. The T2 meeting will involve only body composition measurement. Study outcomes will include body mass and composition (including body fat percent), lipid profile, and the expression of genes related to lipid metabolism in adipose tissue and peripheral blood mononuclear cells. conditions: Overweight and Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Betaine name: Placebo measure: Body composition measure: Body mass measure: Waist and hips circumference measure: Lipid profile measure: Gene expression measure: Liver function test measure: Dietary intake sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Poznan University of Life Sciences city: Poznań zip: 60-637 country: Poland name: Agata Chmurzynska role: CONTACT phone: +48 618466181 email: agata.chmurznska@up.poznan.pl name: Agata Chmurzynska role: PRINCIPAL_INVESTIGATOR name: Emilia Zawieja role: SUB_INVESTIGATOR name: Monika Młodzik-Czyżewska role: SUB_INVESTIGATOR name: Paweł Juszczak role: SUB_INVESTIGATOR lat: 52.40692 lon: 16.92993 hasResults: False